NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









BioSkryb Genomics

BioSkryb Genomics

Private
Durham, North CarolinaHealthcare & Life Scienceshttps://www.bioskryb.com/

Last Round

Series A

May 1, 2025

Total Funding Raised

$31.5M

Company Overview

BioSkryb Genomics is a biotechnology company that develops a genome amplification system leveraging cellular heterogeneity to provide scientists and clinicians with comprehensive insights into the genome, transcriptome, and proteome of individual cells for the study of complex diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Biotech Equipment, Precision Medicine

Business Model

B2B

Customer Profile

Hardware Sales, Services & Consulting, Subscription SaaS

AI Layer

Application

Keywords

single-cell genomicssingle-cell multiomicsprimary template-directed amplificationPTAwhole genome amplificationsingle-cell sequencingbioinformatics platformsingle-cell analysisgenomic analysismethylome analysissingle-cell kitslibrary preparationsingle-cell workflowsingle-cell techmultiomics datagenomic research tools

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

BioSkryb Genomics Comparables

Compare BioSkryb Genomics with similar companies based on industry and business-model similarity.

BioSkryb Genomics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Mission Bio
83%
Xingeyuan Biotechnology
79%
Atrandi Biosciences
79%

BioSkryb Genomics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AMay 1, 2025
SeedJan 9, 2020

Key People

Founding team and executive leadership

Robert Kaizerman

Chief Operating Officer

Executive Team

BioSkryb Genomics Investors

Notable investors and investment history

BioSkryb Genomics investors
InvestorRounds
Anzu PartnersSeries A, Seed
Wilson Sonsini Goodrich & RosatiSeed, Series A
Seed HealthcareSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Oct 7, 2025

    Partnered with Eremid Genomic Services for new ResolveSEQ LongRead solution.

  • Oct 7, 2025

    Launched ResolveSEQ LongRead solution with Eremid Genomic Services.

BioSkryb Genomics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

BioSkryb Genomics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about BioSkryb Genomics's valuation, stock price, and market status.

Firmographic Details

HeadquartersDurham, North Carolina
Employee Range40
Year Founded2018
Last FundingMay 1, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.